Syngene International Ltd management interview: Syngene Q2 Profit Falls 52% To ₹32 Crore As Lower Zoetis Revenue, Forex Losses Hit Margins
Business Today, 2026-10-28. Video: https://www.youtube.com/watch?v=vGMryh7SiFM
- FY25 revenue: Syngene expects a single-digit rupee degrowth for the full year, mainly because Zoetis will take lower volumes of Librela than last fiscal. Growth in CDMO is expected to offset some of that decline.
- EBITDA margins: Operating EBITDA margin rose to 18% in Q2 from 12% in Q1, supported by revenue growth and cost optimization. Excluding hedge losses, management expects normalized margins in the mid-20s; hedge losses will continue to affect the second half.
- Capacity investment: Syngene invested around ₹200 crore in capex in the first half, with second-half spending expected to be higher. Investment spans biologics and small-molecule manufacturing, discovery infrastructure, AI automation and digitalization.
- CDMO opportunity: CDMO is expected to be the main short- to mid-term growth driver, with management citing a rebuilding pipeline and customer interest in China-plus-1 strategies amid geopolitical shifts and the BIOSECURE Act. The company has 3 biologics manufacturing facilities across Bangalore and Bayview.
- Bayview ramp-up: Bayview is expected to take 2 to 3 years to ramp up; drug-substance batches for its first customer are planned for next fiscal, with commercial revenue and profitability expected in the next 2 to 3 years. Syngene is also adding peptide and oligonucleotide commercial manufacturing facilities in Mangalore.